Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

The FDA’s approval of CASGEVY for children as young as two expands Vertex’s pediatric mandate and opens treatment to roughly 5,500 U.S. patients, strengthening its competitive position in gene therapy. Vertex’s network of over 75 authorized centers and coordination with clinicians signal readiness for a timely commercial rollout, which could drive early revenue capture. In parallel, Vertex disclosed a $10 billion all‑cash bid for Crinetics, adding new therapeutic assets that could broaden its pipeline and enhance future revenue streams. The acquisition will require regulatory clearance and integration, potentially affecting cash flow and earnings guidance in the near term. RBC Capital’s lift of the price target to $577 reflects confidence in the pipeline and earnings outlook, underscoring bullish sentiment. The cystic fibrosis market continues to grow, with Vertex’s CFTR modulators maintaining a competitive edge, though pricing barriers and gene‑therapy opportunities remain key factors. Over the next 1–10 trading days, the market will focus on the timing of CASGEVY commercial rollout, reimbursement decisions, and progress on the Crinetics acquisition. Watch for FDA guidance on reimbursement, the first commercial launch dates, and any regulatory updates on the Crinetics deal to gauge near‑term valuation moves.

VRTX|Company Info

Sector

Healthcare

Industry

Biotechnology

Exchange

NMS

Country

United States

Website

vrtx.com

Symbol

VRTX

Description

Vertex Pharmaceuticals is a biotechnology company focused on the development and commercialization of innovative therapies, with a strong emphasis on treating cystic fibrosis (CF). Its core value proposition lies in providing transformative treatments for CF patients, offering a portfolio of approved medications like TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which address various patient populations. Beyond CF, Vertex is actively expanding its pipeline with promising candidates for conditions such as sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and APOL1-mediated kidney disease, among others. The company distributes its products through specialty pharmacies and distributors, as well as directly to healthcare providers. Strategic collaborations with other biotech firms further enhance its research and development capabilities.

VRTX|Earnings Snapshot

Earnings Summary

Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies, with a strong emphasis on cystic fibrosis treatments such as TRIKAFTA/KAFTRIO and a growing pipeline in rare diseases. The company operates in the healthcare sector, delivering specialty pharmaceuticals through a network of distributors and specialty pharmacies. In Q4 2024 Vertex reported earnings per share of $3.98 versus an estimate of $4.02 and revenue of $2.91 billion, slightly missing consensus; the following quarter, Q1 2025, the company again missed EPS expectations with $4.06 against an estimate of $4.29 while revenue rose to $2.77 billion, reflecting modest top‑line growth. Q2 2025 saw a reversal with EPS of $4.52 beating an estimate of $4.25 and revenue of $2.96 billion, followed by Q3 2025 where EPS climbed to $4.80 versus an estimate of $4.58 and revenue reached $3.08 billion. The most recent quarter, Q4 2025, delivered EPS of $5.03 against an estimate of $5.17 and revenue of $3.19 billion, a 10.4% year‑over‑year increase, while Q1 2026 posted EPS of $4.47 beating an estimate of $4.39 and revenue of $2.99 billion, a decline from the prior quarter. Historically, Vertex has posted double‑digit revenue growth each year, with EPS rising from $3.98 in 2024 to $5.03 in 2025, and the company has maintained a streak of consecutive revenue increases since 2019, though it has experienced a mix of EPS beats and misses. Recent news highlights the FDA approval of CASGEVY for children as young as two, expanding Vertex’s pediatric mandate, and the $10 billion all‑cash acquisition of Crinetics, adding late‑stage assets that could broaden its revenue base. Investors should watch the upcoming earnings guidance for commentary on CASGEVY commercial rollout timelines, reimbursement decisions, and the integration progress of Crinetics, as these factors will shape the company’s near‑term valuation and earnings trajectory.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$4.73	-	-
Q1'26	$4.39	$4.47	+1.7%
Q4'25	$5.17	$5.03	-2.7%
Q3'25	$4.58	$4.80	+4.9%
Q2'25	$4.25	$4.52	+6.3%
Q1'25	$4.29	$4.06	-5.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$3.3B	-	-
Q1'26	$3.1B	$3.0B	-3.4%
Q4'25	$3.2B	$3.2B	-1.5%
Q3'25	-	$3.1B	-
Q2'25	-	$3.0B	-
Q1'25	-	$2.8B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

VRTX Stock Snapshot

VRTX is currently trading at $487.29, giving Vertex Pharmaceuticals Incorporated a market cap of 123.92B and a P/E ratio of 28.6. Today's range spans $484.33–$498.49, with shares opening at $498.21 and moving up $2.00 (0.4%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 81/100.

Over the past year VRTX has traded between $362.50 and $533.67 - the current price is +34.4% off the 52-week low and -8.7% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $554.56 (range $350.00–$641.00), implying upside of +13.8%.

What VRTX has right now - BUY signal, 68/100 technical score, bullish sentiment at 81/100, price $487.29 (in the upper portion of its 52-week range) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 28.6) At 123.92B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $362.50–$533.67.

The combination of a BUY signal (68/100) and bullish news sentiment (81/100) puts VRTX on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 123.92B in Healthcare market cap without immediately moving the stock. At $487.29 (in the upper portion of its 52-week range in the $362.50–$533.67 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

News Sentiment Analysis

Sentiment gathered from recent headlines

81/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Vertex Pharmaceuticals (VRTX) recently secured a label expansion for its gene‑editing therapy Casgevy, extending indications to patients as young as two with sickle cell disease and transfusion‑dependent beta‑thalassemia. The approval adds roughly 5,500 patients to the company’s addressable market and could accelerate future revenue growth. The company’s shares have rebounded, reaching a new 52‑week high and up 9% YTD, suggesting market confidence in the expanded product pipeline.

What did this article say?

The article highlights Vertex Pharmaceuticals’ impressive decade-long performance, showing that a $1,000 investment would have grown substantially. It underscores the company’s strong pipeline and consistent product launches as key drivers of this growth. The analysis compares VRTX’s returns to broader market indices, illustrating its outperformance. Long-term investors can view VRTX as a case study of sustained value creation.

What did this article say?

Vertex Pharmaceuticals completed a $10 billion acquisition, positioning the company to expand its rare disease portfolio. The deal signals confidence in the pipeline and may unlock additional blockbuster candidates. Investors should monitor upcoming product approvals and the integration timeline.

What did this article say?

On July 1, the FDA approved CASGEVY’s expanded use for children as young as two with sickle cell disease or beta‑thalassemia, opening treatment to roughly 5,500 U.S. patients. Vertex has built a network of over 75 authorized centers to deliver the therapy and is coordinating with clinicians to manage early access. The company is pursuing similar label extensions in the U.K. and Saudi Arabia, which could broaden its international footprint. The approval strengthens VRTX’s pipeline and positions it as a leader in gene‑therapy for hematologic disorders. Investors should watch for the timing of commercial rollout and reimbursement outcomes in key markets.

What did this article say?

Vertex Pharmaceuticals disclosed a $10 billion all‑cash offer to acquire Crinetics Pharmaceuticals, prompting Crinetics shares to surge 99% this week. The deal expands VRTX’s pipeline in the targeted therapeutic area and could enhance its revenue prospects. The acquisition will require regulatory clearance and integration planning, which may affect VRTX’s cash position and earnings guidance in the near term.

What did this article say?

RBC Capital lifted its price target for Vertex Pharmaceuticals (VRTX) to $577 from $570, signaling a bullish stance on the company’s near‑term prospects. The upgrade follows recent positive developments in VRTX’s pipeline, including the anticipated launch of its next‑generation cystic fibrosis therapy. Analysts also cited improved earnings guidance and a favorable macro environment for specialty pharma. The new target represents a 1.3% upside from the prior level, suggesting confidence in the company’s growth trajectory. Investors should monitor upcoming earnings releases and regulatory approvals for further confirmation.

What did this article say?

The cystic fibrosis market is growing due to rising prevalence and advances in targeted therapies. Vertex Pharmaceuticals is highlighted among leading players, offering CFTR modulators that improve patient outcomes. High costs and limited access remain challenges, while gene therapy presents future opportunities. Investors should monitor market penetration and pricing dynamics in emerging regions.

What did this article say?

Vertex Pharmaceuticals paid a 102% premium to acquire Crinetics, a rare‑disease biotech, underscoring its strategy to diversify beyond cystic fibrosis. The transaction reflects a broader trend of large pharma targeting biotech assets amid patent expirations. Traders should watch for Crinetics’ product development milestones and the impact on VRTX’s earnings.

What did this article say?

Vertex Pharmaceuticals is broadening its drug pipeline beyond cystic fibrosis. The company is advancing Casgevy, a gene‑editing therapy for beta thalassemia and sickle‑cell disease, and Journavx, a non‑opioid pain medication. Additional candidates include Palsonify for acromegaly and povetacicept targeting IgA nephropathy. These developments signal a strategic shift toward diverse therapeutic areas, potentially mitigating reliance on its cystic fibrosis portfolio.

What did this article say?

Vertex Pharmaceuticals’ $10 billion purchase of Crinetics may leave the stock undervalued by up to 36%, according to valuation models. The deal expands Vertex’s rare disease and endocrinology capabilities, potentially unlocking new revenue streams. Current market pricing appears to have already priced in significant upside, but analysts suggest further gains if integration proceeds smoothly. Investors should track the progress of the acquisition and any related earnings guidance. The valuation gap presents a potential buying opportunity for long‑term holders.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

VRTX·Vertex Pharmaceuticals Incorporated

EPS

Revenue

VRTX Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More